Drug Price Trends for ELURYNG

Average Pharmacy Cost for ELURYNG

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
ELURYNG VAGINAL RING	65162-0469-32	47.89079	EACH	2026-06-17
ELURYNG VAGINAL RING	65162-0469-35	47.89079	EACH	2026-06-17
ELURYNG VAGINAL RING	65162-0469-32	48.54106	EACH	2026-05-20
ELURYNG VAGINAL RING	65162-0469-35	48.54106	EACH	2026-05-20

Best Wholesale Price for ELURYNG

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Unit	Dates	Price Type
ELURYNG	AvKare, LLC	65162-0469-35	1X3	167.40			2023-06-15 - 2028-06-14	FSS

Error:Operation timed out after 1001 milliseconds with 0 bytes received

Market Analysis and Price Projections for EluRyng

Last updated: July 27, 2025

Introduction

EluRyng, the first generic version of NuvaRing, has made significant waves in the contraceptive market since its approval by the FDA in 2019. This innovative vaginal ring offers women a convenient and effective birth control option, combining hormonal contraception with ease of use. As we delve into the market analysis and price projections for EluRyng, we'll explore its impact on the pharmaceutical industry, consumer preferences, and the future of contraceptive methods.

Market Overview

The vaginal ring market, which includes EluRyng, has shown impressive growth in recent years. In 2022, the market was valued at $1,932.9 million and is projected to reach $2,791.2 million by 2030, growing at a compound annual growth rate (CAGR) of 4.7%[3]. This growth trajectory underscores the increasing acceptance and demand for innovative contraceptive methods.

"The vaginal rings market, which includes EluRyng, was valued at $1,932.9 million in 2022 and is projected to reach $2,791.2 million by 2030, growing at a Compound Annual Growth Rate (CAGR) of 4.7% during the forecast period[3]."

EluRyng's Market Position

As a generic version of NuvaRing, EluRyng has quickly established itself as a key player in the contraceptive market. Its approval by the FDA in 2019 marked a significant milestone, offering consumers a more affordable alternative to the brand-name product[1]. Amneal Pharmaceuticals, the manufacturer of EluRyng, has positioned the product as part of its strategy to launch 15 new, complex products over an 18 to 24-month period[1].

Pricing Analysis

Current Pricing

The pricing of EluRyng reflects its position as a generic alternative to NuvaRing. For cash-paying customers, the cost of EluRyng is approximately $155 for a supply of 3 rings, with each ring costing about $51.50[2][5]. This pricing strategy makes EluRyng an attractive option for consumers seeking a more affordable contraceptive solution.

Comparison to Brand-Name Products

When compared to the brand-name NuvaRing, EluRyng offers significant cost savings. Before the introduction of generic versions, NuvaRing's annual sales in the U.S. were approximately $976 million for the 12 months ended October 31, 2019[1]. The entry of EluRyng and other generic alternatives has likely put downward pressure on prices in this market segment.

Insurance and Discount Programs

The actual cost to consumers can vary significantly based on insurance coverage and available discount programs. Many insurance plans cover contraceptives, including vaginal rings, which can substantially reduce out-of-pocket expenses for users. Additionally, discount cards and manufacturer savings programs can offer further cost reductions, making EluRyng even more accessible to a broader range of consumers[2][5].

Market Drivers

Several factors are contributing to the growth of the vaginal ring market, including EluRyng:

1. Increasing Acceptance of Contraceptives: Shifting attitudes towards contraception, particularly among younger demographics, are driving market growth[4].

2. Rising Disposable Incomes: Higher disposable incomes, especially in developing economies, are enabling more women to access advanced contraceptive methods[4].

3. Growing Awareness: Increased education and awareness about contraceptive options are leading more women to consider alternatives to traditional birth control methods[4].

4. Convenience Factor: The ease of use and low maintenance requirements of vaginal rings like EluRyng appeal to many users seeking hassle-free contraception.

5. Technological Advancements: Ongoing improvements in drug delivery systems are enhancing the efficacy and safety of vaginal rings.

Market Challenges

Despite the positive growth outlook, the EluRyng market faces some challenges:

1. Competition from Other Contraceptive Methods: The availability of various contraceptive options, including oral contraceptives and long-acting reversible contraceptives (LARCs), creates a competitive landscape.

2. Regulatory Hurdles: Stringent regulatory requirements for approval and ongoing monitoring of contraceptive products can impact market entry and ongoing costs.

3. Side Effects Concerns: As with all hormonal contraceptives, potential side effects may deter some users from choosing EluRyng.

4. Access Issues: In some regions, access to newer contraceptive methods like EluRyng may be limited due to cost or availability constraints.

Regional Market Analysis

The global market for vaginal rings, including EluRyng, shows varying trends across different regions:

North America

North America is expected to hold the largest market share for vaginal rings. The United States, in particular, has shown strong adoption of these contraceptive methods, driven by high awareness levels and favorable insurance coverage[4].

Europe

Europe represents a significant market for vaginal rings, with high acceptance rates of hormonal contraceptives and strong healthcare infrastructure supporting their use.

Asia Pacific

The Asia Pacific region is projected to experience rapid growth in the vaginal ring market. Factors such as increasing disposable incomes, changing attitudes towards contraception, and growing awareness are driving this trend[4].

Latin America and Middle East & Africa

These regions are also showing growth in the vaginal ring market, albeit at a slower pace compared to more developed regions. Increasing healthcare access and changing societal norms are contributing to market expansion.

Future Price Projections

While specific long-term price projections for EluRyng are not available, several factors are likely to influence its pricing in the coming years:

1. Generic Competition: As more generic versions of NuvaRing enter the market, prices are likely to face downward pressure.

2. Manufacturing Costs: Advances in production techniques may lead to reduced manufacturing costs, potentially resulting in lower prices for consumers.

3. Market Demand: Increasing acceptance and demand for vaginal rings could lead to economies of scale, potentially reducing prices.

4. Healthcare Policies: Changes in healthcare policies and insurance coverage for contraceptives could impact the out-of-pocket costs for consumers.

5. Inflation and Economic Factors: General economic conditions and inflation rates will play a role in future pricing.

Competitive Landscape

The market for vaginal rings is competitive, with several key players vying for market share:

1. Merck & Co., Inc.: The original manufacturer of NuvaRing, Merck remains a significant player in the market.

2. Amneal Pharmaceuticals, Inc.: As the manufacturer of EluRyng, Amneal has quickly established itself as a key competitor in the generic segment.

3. Teva Pharmaceutical Industries Ltd.: Another major player in the generic pharmaceutical market, Teva has also entered the vaginal ring space.

4. Pfizer Inc.: While not currently a major player in vaginal rings, Pfizer's strong presence in women's health makes it a potential future competitor.

5. TherapeuticsMD, Inc.: A company focused on women's health, TherapeuticsMD is actively developing new contraceptive technologies.

Innovation and Research & Development

The future of the vaginal ring market, including EluRyng, will be shaped by ongoing innovation and R&D efforts. Areas of focus include:

1. Extended-Use Formulations: Developing rings that can be used for longer periods, potentially up to one year.

2. Multi-Purpose Prevention Technologies: Rings that combine contraception with protection against sexually transmitted infections.

3. Smart Rings: Incorporating digital technologies for improved tracking and adherence.

4. Personalized Medicine: Tailoring hormone doses to individual user needs.

Market Outlook

The outlook for EluRyng and the broader vaginal ring market remains positive. The combination of increasing acceptance, growing awareness, and ongoing innovation suggests continued growth in the coming years. As more women seek convenient and effective contraceptive options, products like EluRyng are well-positioned to meet this demand.

Key Takeaways

• EluRyng, as a generic version of NuvaRing, has quickly established itself in the contraceptive market since its FDA approval in 2019.
• The vaginal ring market is projected to grow from $1,932.9 million in 2022 to $2,791.2 million by 2030, with a CAGR of 4.7%.
• Current pricing for EluRyng is approximately $155 for a three-ring supply, offering a more affordable alternative to brand-name products.
• Market growth is driven by factors such as increasing acceptance of contraceptives, rising disposable incomes, and growing awareness.
• Regional variations in market growth exist, with North America leading and Asia Pacific showing rapid expansion.
• Future pricing will be influenced by generic competition, manufacturing costs, market demand, and healthcare policies.
• Ongoing innovation in extended-use formulations, multi-purpose prevention technologies, and smart rings will shape the future of the market.

FAQs

1. Q: How does EluRyng compare to other contraceptive methods in terms of effectiveness? A: EluRyng is highly effective, with a Pearl Index of 0.65, indicating a low pregnancy rate among users. This effectiveness is comparable to other hormonal contraceptive methods when used correctly.

2. Q: Can EluRyng be used continuously without the one-week break? A: While EluRyng is typically used for three weeks followed by a one-week break, some healthcare providers may recommend continuous use for certain patients. Always consult with a healthcare professional before altering the recommended usage.

3. Q: Are there any environmental concerns associated with EluRyng disposal? A: Like other medical devices, proper disposal of EluRyng is important. Users should follow local guidelines for disposing of medical waste. Some pharmacies may offer take-back programs for proper disposal.

4. Q: How might future technological advancements impact the pricing of EluRyng and similar products? A: Technological advancements could lead to more efficient manufacturing processes, potentially reducing production costs. However, the development of new features or improved formulations might also justify higher prices for next-generation products.

5. Q: What role do patient assistance programs play in making EluRyng accessible to more users? A: Patient assistance programs, offered by manufacturers or non-profit organizations, can significantly reduce the cost of EluRyng for eligible users. These programs play a crucial role in improving access to contraceptives for those who might otherwise find them unaffordable.

Sources cited: [1] https://investors.amneal.com/news/press-releases/press-release-details/2019/Amneal-Receives-Abbreviated-New-Drug-Application-Approval-for-EluRyng-the-First-Generic-NuvaRing/default.aspx [2] https://www.medthority.com/fda/e/eluryng/eluryng-ethinyl-estradiol-.015-mgd-amneal-pharmaceuticals-llc [3] https://www.drugpatentwatch.com/p/drug-price/drugname/ELURYNG+VAGINAL+RING [4] https://www.alliedmarketresearch.com/drug-eluting-stents-market-A10604 [5] https://www.pharmacytimes.com/view/fda-approves-first-generic-version-of-nuvaring